N,N,N',N'-tetraisopropyl-1-cyclohexyloxyphosphanediamine | 1257326-97-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N,N,N',N'-tetraisopropyl-1-cyclohexyloxyphosphanediamine
• 英文别名: N-[cyclohexyloxy-[di(propan-2-yl)amino]phosphanyl]-N-propan-2-ylpropan-2-amine
• CAS: 1257326-97-8
• 化学式: C₁₈H₃₉N₂OP
• 分子量: 330.494
• InChiKey: FPUFHXURKCLAEP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N,N,N',N'-tetraisopropyl-1-cyclohexyloxyphosphanediamine 在 4,5-二氰基咪唑 作用下， 以 乙腈 为溶剂， 生成
  参考文献：
  名称：

  β-d-2′-α-F-2′-β-C-Methyl-6-O-substituted 3′,5′-cyclic phosphate nucleotide prodrugs as inhibitors of hepatitis C virus replication: A structure–activity relationship study

  摘要：

  The 3',5'-cyclic phosphate prodrug 9-[beta-D-2'-deoxy-2'-alpha-fluoro-2'-beta-C-methylribofuranosyl]-2-amino-6-ethoxypurine, PSI-3529381, has demonstrated promising anti-HCV efficacy in vitro and in human clinical trials. A structure-activity relationship study of the nucleoside 3',5'-cyclic phosphate series of beta-D-2'-deoxy-2'-alpha-fluoro-2'-beta-C-methylribofuranosyl nucleoside prodrugs was undertaken and the anti-HCV activity and in vitro safety profile were assessed. Cycloalkyl 3',5'-cyclic phosphate prodrugs were shown to be significantly more potent as inhibitors of HCV replication than branched and straight chain alkyl 3',5'-cyclic phosphate prodrugs. No cytotoxicity and mitochondrial toxicity for prodrugs 12, 13 and 19 were observed at concentrations up to 100 mu m in vitro. Cycloalkyl esters of 3',5'-cyclic phosphate nucleotide prodrugs demonstrated the ability to produce high levels of active triphosphate in clone-A cells and primary human hepatocytes. Compounds 12, 13 and 19 also demonstrated the ability to effectively deliver in vivo high levels of active nucleoside phosphates to rat liver. (C) 2012 Elsevier Ltd. All rights reserved. .

  DOI：

  10.1016/j.bmcl.2012.07.066

文献信息

• [EN] 5-FLUOROURACIL COMPOUNDS<br/>[FR] COMPOSÉS DE 5-FLUOROURACILE
  申请人：NUCORION PHARMACEUTICALS INC

  公开号：WO2019143860A1

  公开（公告）日：2019-07-25

  Provided herein are 5-fluorouracil derived acetal and hemiaminal ether compounds, their preparation and their uses, such as treating liver diseases or various types of cancer.

  本文提供了5-氟尿嘧啶衍生的缩醛和半胺醚化合物，它们的制备和用途，例如治疗肝病或各种类型的癌症。
• 5-FLUOROURACIL COMPOUNDS
  申请人：NUCORION PHARMACEUTICALS, INC.

  公开号：US20200399227A1

  公开（公告）日：2020-12-24

  Provided herein are 5-fluorouracil derived acetal and hemiaminal ether compounds, their preparation and their uses, such as treating liver diseases or various types of cancer.